THRESHOLD ANALYSIS AND PROGRAMS FOR PREVENTION OF HIV-INFECTION

被引:38
作者
HOLTGRAVE, DR [1 ]
QUALLS, NL [1 ]
机构
[1] CTR DIS CONTROL & PREVENT, OFF DIRECTOR, OFF HIV AIDS, ATLANTA, GA 30341 USA
关键词
HIV; AIDS; PREVENTION; THRESHOLD ANALYSIS; COST-UTILITY ANALYSIS;
D O I
10.1177/0272989X9501500402
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. Measuring the economic effectiveness of HIV-infection prevention activities poses special challenges in terms of behavioral change acid health outcomes assessment. Methods. One way to address this difficulty is to employ threshold analysis to determine a level of cost per HIV infection averted above which society would seem unwilling to pay. The authors employ a cost-utility analytic framework to determine a monetary threshold for HIV prevention programs, subject base-case results to sensitivity analyses, and apply these results to the Centers for Disease Control and Prevention's fiscal year 1993 budget for extramural HIV prevention programs. Results. The monetary threshold for cost per HIV infection averted was calculated to be $417,000 in 1993 dollars, and ranged from $185,000 to $648,000 depending upon the dollar amount society would be willing to pay per quality-adjusted life year gained. Conclusions. Economic evaluations of particular HIV-infection prevention activities at least can begin by determining whether their levels of effectiveness are above or below this derived monetary threshold, and refinements beyond this dichotomous evaluation can proceed as further data become available.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 40 条
[1]   AIDS AND ABSOLUTISM - THE DEMAND FOR PERFECTION IN PREVENTION [J].
CATES, W ;
HINMAN, AR .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (07) :492-494
[2]   HEALTH-RELATED QUALITY-OF-LIFE IN PERSONS WITH ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME [J].
CLEARY, PD ;
FOWLER, FJ ;
WEISSMAN, J ;
MASSAGLI, MP ;
WILSON, I ;
SEAGE, GR ;
GATSONIS, C ;
EPSTEIN, A .
MEDICAL CARE, 1993, 31 (07) :569-580
[3]  
Coyle SL, 1991, EVALUATING AIDS PREV
[4]   LONGITUDINAL-STUDY ON THE QUALITY-OF-LIFE OF SYMPTOMATIC HIV-INFECTED PATIENTS IN A TRIAL OF ZIDOVUDINE VERSUS ZIDOVUDINE AND INTERFERON-ALPHA [J].
DEBOER, JB ;
VANDAM, FSAM ;
SPRANGERS, MAG ;
FRISSEN, PHJ ;
LANGE, JMA .
AIDS, 1993, 7 (07) :947-953
[5]  
DRUMMOND M, 1990, EC ASPECTS AIDS HIV, P107
[6]  
Drummond MF, 1992, METHODS EC EVALUATIO
[7]   DIFFERENCES IN MORTALITY-RATES AND CAUSES OF DEATH BETWEEN HIV-POSITIVE AND HIV-NEGATIVE INTRAVENOUS-DRUG-USERS [J].
ESKILD, A ;
MAGNUS, P ;
SAMUELSEN, SO ;
SOHLBERG, C ;
KITTELSEN, P .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1993, 22 (02) :315-320
[8]   OPTIMAL MANAGEMENT STRATEGIES FOR HIV-INFECTED PATIENTS WHO PRESENT WITH COUGH OR DYSPNEA - A COST-EFFECTIVENESS ANALYSIS [J].
FREEDBERG, KA ;
TOSTESON, ANA ;
COTTON, DJ ;
GOLDMAN, L .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1992, 7 (03) :261-272
[9]   DESCRIBING THE HEALTH-RELATED QUALITY-OF-LIFE IMPACT OF HIV-INFECTION - FINDINGS FROM A STUDY USING THE HIV OVERVIEW OF PROBLEMS EVALUATION SYSTEM (HOPES) [J].
GANZ, PA ;
SCHAG, CAC ;
KAHN, B ;
PETERSEN, L ;
HIRJI, K .
QUALITY OF LIFE RESEARCH, 1993, 2 (02) :109-119
[10]   EPIDEMIOLOGY OF LATE PRESENTATION OF HIV-INFECTION IN WESTERN AUSTRALIA [J].
GILLIEATT, SJ ;
MALLAL, SA ;
FRENCH, MAH ;
DAWKINS, RL .
MEDICAL JOURNAL OF AUSTRALIA, 1992, 157 (02) :117-118